Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

87 results about "Adenosine a" patented technology

Myocardial perfusion imaging methods and compositions

InactiveUS20050020915A1Facilitate myocardial imagingBiocideCarbohydrate active ingredientsCardiac muscleAgonist
A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
Owner:GILEAD SCI INC +1

Methods to Protect Skeletal Muscle Against Injury

InactiveUS20080312180A1BiocideMuscular disorderDiseaseAdenosine A3 Receptor Agonists
Disclosed herein are compositions and methods for the treatment of skeletal muscle and / or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of skeletal muscle. Adenosine A3 receptor agonists are used treat subjects with skeletal muscle ischemia and reperfusion (I / R) injuries, individuals with skeletal muscle disorders, and individuals suffering from skeletal muscle injury resulting from physical exertion.
Owner:UNIV OF CONNECTICUT +1

Prophylatic and/or therapeutic agents for chronic musculoskeletal pain

A prophylactic and / or therapeutic agent for diseases accompanied by chronic musculoskeletal pain comprising as an active ingredient a compound having an adenosine A2A receptor antagonistic action, for example, represented by the following formula (I) (wherein R1, R2 and R3 are the same or different, each representing a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R4 represents cycloalkyl, —(CH2)n—R5 or the following formula (II); and X1 and X2 are the same or different, each representing an oxygen atom or a sulfur atom) or a pharmaceutically acceptable salt thereof.
Owner:KYOWA HAKKO KIRIN CO LTD

Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening

The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.
Owner:NEW YORK UNIV

Derivatives of triazoly-imidazopyridine and of the triazolypurines useful as ligands of the adenosine A2a receptor and their use as medicaments

InactiveUS20070249638A1BiocideNervous disorderDiseaseAryl
Compounds of formula (I) wherein: X is N; R1 is C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl; R2 is hydrogen, C1-C6 linear or branched alkyl or C1-C6 linear or branched alkenyl, C6-C14 aryl or C6-C14 aryl(C1-C6) linear or branched alkyl or C6-C14 aryl(C1-C6) linear or branched alkenyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting of halogen, hydroxy, C1-C6 alkoxy linear or branched or C1-C6 alkenyloxy linear or branched, amino, optionally mono- or disubstituted with C1-C6 linear or branched alkyl; R3 is NH2, NHR4; R4 is C1-C6 alkyl or C1-C6 hydroxyalkyl, C1-C3 alkoxyalkyl, amino(C1-C6)alkyl, where the amino group is optionally substituted with one or two C1-C3 linear or branched alkyl groups, or with one or two C2-C3 alkenyl groups C6-C14 aryl or C6-C14 aryl(C1-C6)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting by halogen, hydroxy, C1-C6 alkoxy linear or branched or C1-C6 alkenyloxy linear or branched, amino, mono- or di-substituted with C1-C6 alkyl linear or branched or C1-C6 alkenyl linear or branched; and their pharmaceutically acceptable salts. These compounds are antagonists of the adenosine A2a receptor and useful as medicaments, in particular for the treatment of Parkinson's disease.
Owner:SIGMA TAU IND FARMACEUTICHE RIUNITE SPA

Use of A2A adenosine receptor agonists

InactiveUS20060084625A1Increase peak flow velocityBiocideEchographic/ultrasound-imaging preparationsRegadenosonCardiac muscle
Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.
Owner:TPG AXON LEX SUB TRUST +1

Methods of treating patients suffering from movement disorders

ActiveUS20060178379A1Reducing and suppressing adverse effectiveness of L-DOPAShorten closing timeBiocideNervous disorderAdenosineDisease patient
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and / or a COMT inhibitor and / or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and / or a COMT inhibitor, and / or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
Owner:KYOWA HAKKO KIRIN CO LTD

Compounds specific to adenosine A3 receptor and uses thereof

This invention pertains to compounds which specifically inhibit the adenosine A3 receptor and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
Owner:OSI PHARMA INC

Compounds specific to adenosine a1 and a3 receptors and uses thereof

This invention pertains to compounds which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
Owner:OSI PHARMA INC

Method of treating an anxiety disorder

Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
Owner:KYOWA HAKKO KIRIN CO LTD

Technique of chemical synthesis of producing adenosine

A process for preparing adenosine from inosine by chemical synthesis method includes such steps as acetylating by excessive acetic anhydride under existence of anhydrous sodium acetate to obtain acetylinosine, chlorinating it by trichloroxyphosphate in pyridine to obtain chloro-acetylinosine, ammonolyzing in ammonia-methanol solution to obtain coarse adenosine, and refining. Its advantage is high output rate.
Owner:JINAN MINGXIN PHARMA

Adenosine A3 receptor agonists

InactiveUS6914053B2Avoid side effectsAvoid actionBiocideNervous disorderArylAdenosine A3 Receptor Agonists
Disclosed are novel adenosine A3 receptor agonists of Formula I: wherein:R is hydrogen or lower alkyl;R1 is optionally substituted lower alkoxy or optionally substituted cycloalkyloxy;R2 is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted trialkylsilyl; andR3 is hydroxymethyl or R4R5NC(Q)—;in which R4 and R5 are hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
Owner:CV THERAPEUTICS INC

Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments

Compounds of formula (I)wherein: X is N;R1 is C1–C6 linear or branched alkyl or C1–C6 linear or branched alkenyl; R2 is hydrogen, C1–C6 linear or branched alkyl or C1–C6 linear or branched alkenyl, C6–C14 aryl or C6–C14 aryl(C1–C6) linear or branched alkyl or C6–C14 aryl(C1–C6) linear or branched alkenyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting of halogen, hydroxy, C1–C6 alkoxy linear or branched or C114 C6 alkenyloxy linear or branched, amino, optionally mono- or disubstituted with C1–C6 linear or branched alkyl; R3 is NH2, NHR4; R4 is C1–C6 alkyl or C1–C6 hydroxyalkyl, C1–C3 alkoxyalkyl, amino(C1–C6)alkyl, where the amino group is optionally substituted with one or two C1–C3 linear or branched alkyl groups, or with one or two C2–C3 alkenyl groups C6–C14 aryl or C6–C14 aryl(C1–C6)alkyl, with the aryl group optionally substituted by one or more substituents, either the same or different, selected from the group consisting by halogen, hydroxy, C1–C6 alkoxy linear or branched or C1–C6 alkenyloxy linear or branched, amino, mono- or di-substituted with C1–C6 alkyl linear or branched or C1–C6 alkenyl linear or branched; and their pharmaceutically acceptable salts. These compounds are antagonists of the adenosine A2a receptor and useful as medicaments, in particular for the treatment of Parkinson's disease.
Owner:SIGMA TAU IND FARMACEUTICHE RIUNITE SPA

Medicinal compositions

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD

Inhibitor of analgesic tolerance

Provided are: an agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), which comprises a compound having adenosine A2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof as an active ingredient; the agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), wherein the undesirable effect of the opioid-type analgesic (opioid) is analgesic tolerance or constipation; the agent for suppressing an undesirable effect of an opioid-type analgesic (opioid), wherein the undesirable effect of the opioid-type analgesic (opioid) is analgesic tolerance; and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products